论文部分内容阅读
目的:探讨胸痹3号方治疗冠心病稳定型心绞痛的临床疗效,同时研究其对患者血液流变学及血脂指标的影响.方法:将60例稳定型心绞痛患者随机分为对照组和治疗组各30例.两组均予内科常规治疗,治疗组加服胸痹3号方,对照组口服单硝酸异山梨酯缓释胶囊,两组均连续治疗4周.观察两组心绞痛疗效、心电图疗效、血液流变学以及血脂的变化.结果:治疗4周后,治疗组的心绞痛疗效及心电图疗效均优于对照组,差异有统计学意义(P＜0.05);两组血液流变学以及血脂指标治疗前后变化差异均有统计学意义(P＜0.01),且治疗组均优于对照组(P＜0.01).结论:胸痹3号方治疗冠心病稳定型心绞痛患者有较好的疗效,可能与降低血液流变学及血脂指标相关.“,”Objective:To investigate the clinical efficacy of Xiongbifang No.3（胸痹3号方） on stable angina pectoris of coronary artery disease,and to study its effect on Hemorheology and blood lipid indexes.Methods:The 60 cases of stable angina patients were randomly divided into control and treatment groups with 30 cases in each.Patients were treated with conventional therapy in two groups,and the treatment group added Xiongbifang No.3,while the control group with oral Isosorbide Mononitrate Sustained-release Capsules,for 4 weeks.The angina pectoris,electrocardiogram curative effect,blood rheology and blood lipid changes were observed and compared between two groups.Results:after 4 weeks treatment,the treatment group showed better angina and ECG efficacy of than the control group,with significant difference (P＜0.05); the two group of blood rheology and blood lipid indexes showed significant changes (P＜0.05),and the treatment group was better than the control group (P＜0.05).Conclusion:Xiongbifang No.3 have good effect on stable angina pectoris of coronary heart disease,and the efficacy may be associated with a lower blood lipid and blood rheology index.